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ABSTRACT Natural killer (NK) cell-based immuno-
therapy is a promising strategy for cancer treatment,
and caspase-3 is an important effector molecule in NK
cell-mediated apoptosis in cancers. Here, we evaluated
the antitumor effects of NK cell-based immunotherapy
by serial noninvasive imaging of apoptosis using a
caspase-3 sensor in mice with human glioma xeno-
grafts. Human glioma cells expressing both a caspase-3
sensor as a surrogate marker for caspase-3 activation
and Renilla luciferase (Rluc) as a surrogate marker for
cell viability were established and referred to as
D54-CR cells. Human NK92 cells were used as effector
cells. Treatment with NK92 cells resulted in a time- and
effector number-dependent increase in biolumines-
cence imaging (BLI) activity of the caspase-3 sensor in
D54-CR cells in vitro. Caspase-3 activation by NK92
treatment was blocked by Z-VAD treatment in D54-CR
cells. Transfusion of NK92 cells induced an increase of
the BLI signal by caspase-3 activation in a dose- and
time-dependent manner in D54-CR tumor-bearing mice
but not in PBS-treated mice. Accordingly, sequential
BLI with the Rluc reporter gene revealed marked
retardation of tumor growth in the NK92-treatment
group but not in the PBS-treatment group. These data
suggest that noninvasive imaging of apoptosis with a
caspase-3 sensor can be used as an effective tool for
evaluation of therapeutic efficacy as well as for optimi-
zation of NK cell-based immunotherapy.—Lee, H. W.,
Singh, T. D., Lee, S.-W., Ha, J.-H., Rehemtulla, A., Ahn,
B.-C., Jeon, Y.-H., Lee, J. Evaluation of therapeutic
effects of natural killer (NK) cell-based immunother-
apy in mice using in vivo apoptosis bioimaging with a
caspase-3 sensor. FASEB J. 28, 2932–2941 (2014).
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Natural killer (NK) cells are cytotoxic lymphocytes
that are critical to innate immunity (1, 2). The killing
effects of NK cells are regulated by either activating
receptors that identify ligands on target cancer cells or
by inhibitory receptors specific for major histocompat-
ibility complex (MHC) class I molecules on cancer
cells. They play an important role in eliminating target
cells by 2 major mechanisms: perforin/granzymes and
aggregation of target cell death receptors [Fas ligand-
(FasL) or tumor necrosis factor-related apoptosis-in-
ducing ligand (TRAIL)-related receptor; refs. 3–5]. A
combination of perforin and granzyme leads to the
intrinsic apoptosis pathway, which includes sequen-
tial molecular events such as the release of cyto-
chrome c, formation of the apoptosome, and activa-
tion of effector caspase-3, -6, and -7. In addition,
death receptor-mediated apoptosis leads to cell
death through the extrinsic apoptosis pathway, re-
sulting in activation of Bid and caspase-8 and -3 and,
finally, execution of cell death.
The efficacy of NK-based immunotherapy has been
reported to be dependent on the ability to manipulate
the balance of activating/inhibitory receptors on NK
cells and their cognate ligands, as well as the sensitivity
of tumor cells to apoptosis (5–7). Although many
studies have explored their efficacy in anticancer ther-
apy, no clear clinical benefit has been demonstrated
due to several factors, such as alteration of NK cell
functions, chronic inflammation, regulatory T cell hin-
drance, and cytokine imbalance (8). Therefore, a bet-
ter understanding of the mechanisms leading to NK
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therapy failure is required for the development of novel
treatment paradigms to improve therapeutic outcome.
NK cell-mediated death is involved in multiple apo-
ptosis pathways, including intrinsic and extrinsic apo-
ptosis. Although a number of specific assays to detect
apoptosis progression have been developed, all assays
developed to date, including assays based on caspase
activation by a fluorescent substrate, fluorescent reso-
nance energy transfer (FRET) construct-based assays,
phosphatidyl serine exposure assays, assays that detect
DNA-strand breaks, vital dye-based assays (calcein-AM),
and radioprobe-based assays, measure apoptosis pro-
gression based on single-endpoint determinations (9).
These methods determine the level of apoptosis in vitro
and are not amenable to use in animal models, which
hinders comprehensive understanding of the failure of
NK cell therapy. Thus, the development of methods
that can be used in real time is needed for the precise
identification of apoptotic events.
Specialized molecular imaging tools that can reveal
dynamic processes of apoptosis activation may provide
the deconvolution of apoptosis-related biochemical cas-
cades, as well as allow for a better understanding of the
combination of various therapeutic modalities with
NK-cell based therapy. Furthermore, this imaging plat-
form may facilitate the evaluation of several important
factors, such as the determination of effector/target
ratio, cytotoxictiy, adjuvant supplement, and in vivo
therapeutic protocol. Noninvasive imaging of apoptosis
induced by treatment with certain chemotherapeutic
drugs was successfully undertaken in a human glioma
cancer model using a reporter for caspase-3 proteolysis
(10). Based on our recent work, we postulate that
caspase-3-dependent apoptosis activation generated by
NK cell cytotoxicity could also be serially monitored by
a caspase-3 biosensor in living animals noninvasively,
and this system would be very helpful in the prepara-
tion of a preclinical setting of cell therapy.
In this study, we monitored the activation of caspase-
3-dependent apoptosis by NK cell-based immunother-
apy in an animal model of human glioma cancer
expressing a caspase-3 sensor and renilla luciferase in
vitro and in vivo. A molecular bioluminescence imaging
(BLI) approach was undertaken in an effort to more
objectively delineate the response of NK-cell based
therapy through 2 different reporters, in which BLI of
the caspase-3 sensor is used to monitor apoptosis by
measuring caspase-3-linked activation and BLI of the
Renilla luciferase (Rluc) gene is used to measure cell
viability.
MATERIALS AND METHODS
Animals
Pathogen-free 6-wk-old female Balb/c nude mice were ob-
tained from SLC (Shizuoka, Japan). All animal experimental
protocols were approved by the Committee for the Handling
and Use of Animals of Kyungpook National University.
Cell lines
NK92 cells (human IL-2-dependent NK cells) to be used as
effectors were purchased from American Type Culture Col-
lection (ATCC; Manassas, VA, USA) and maintained in 
minimum essential medium without ribonucleosides and
deoxyribonucleosides and supplemented with 2 mM l-glu-
tamine, 1.5 mg/ml sodium bicarbonate, 0.2 mM inositol, 0.1
mM 2-mercaptoethanol, 0.02 mM folic acid, 12.5% horse
serum, and 12.5% fetal bovine serum (Hyclone, Logan, UT,
USA) at 37°C in a 5% CO2 atmosphere.
D54 human glioma cells were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum (Hy-
clone), 1% antibiotic-antimycotic (Gibco, Grand Island, NY,
USA), and GlutaMAX (Gibco) at 37°C in a 5% CO2 atmo-
sphere.
The MDA-MB-231-derived human breast cancer cell line
1833 was cultured in DMEM supplemented with 10% fetal
bovine serum, 1% antibiotic-antimycotic, and GlutaMAX at
37°C in a 5% CO2 atmosphere.
D54 and 1833 cells were transfected with the caspase-3
sensor construct using Fugene 6 (Roche, Aurora, OH, USA),
and stable clones were selected with G418 (Gibco). D54 and
1833 cells that stably expressed the caspase-3 sensor were
further transduced with lentivirus coexpressing Rluc, mcherry, and
puromycin genes under the control of CMV promoter (Ge-
necopoeia, Rockville, MD, USA). Stable clones were selected
with puromycin (Sigma-Aldrich, St. Louis, MO, USA). The
established stable cell lines expressing both the caspase-3
sensor and Rluc gene are herein referred to as D54-CR and
1833-CR cells, respectively.
In vitro bioluminescence imaging
To evaluate apoptosis induction in the stable clones (D54-CR
and 1833-CR cells) by NK92 cells, effector and target cells
were cocultured with growth medium containing 1% Glosen-
sor (Promega, Madison, WI, USA) at different target/effector
(T:E) ratios in white and clear bottom 96-well plates, and BLI
signals were measured at the indicated times using a micro-
plate reader.
For the inhibition studies of caspase-3 activation, D54-CR
cells were plated in white and clear bottom 96-well plates.
After 24 h, the medium was replaced with growth medium
containing 1% Glosensor (Promega). Vehicle, Z-VAD-FMK (a
pan-caspase inhibitor, drug concentration 200 M; Tocris,
Bristol, UK), PD98059 (ERK inhibitor, 10 M; Sigma-Al-
drich), and wortmanin [phosphatidylinositol 3-kinase (PI3K)
inhibitor, 10 M; Sigma-Aldrich] were added to each well for
2 h. NK92 cells were cocultured with D54-CR cells at a T:E
ratio of 1:5, and BLI activity was measured using a microplate
reader at the indicated times.
To monitor caspase-3 activation by stimulated or nonstimu-
lated NK92 cells, NK92 cells were treated with or without a
combination of phorbol 12-myristate 13-acetate (PMA, 10
ng/ml; Sigma-Aldrich) and ionomycin (1 mg/ml; Sigma-
Aldrich) for 2h. Stimulated and nonstimulated-NK92 cells
were coincubated with D54-CR cells at a T:E ratio of 1:2.5, and
BLI activity was measured using a microplate reader at the
indicated times.
FACS analysis
D54-CR cells were plated in 6-well plates and incubated with
rTRAIL (90, 180, 360, and 720 ng/ml) for 6 h. After 24 h, the
cells were trypsinzed and collected by centrifugation. PE-
conjugated cleaved caspase-3 Ab (BD Biosciences, San Jose,
CA, USA) was added to each plate, and caspase-3-positive cells
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were determined using a BD FACSCanto flow cytometer (BD
Biosciences).
To determine the fraction of cleaved caspase-3-positive
cells or annexin-V-positive cells in the D54-CR tumors treated
with either phosphate-buffered saline (PBS) or NK92 cells,
mice were killed and the tumor masses were extracted.
Tumors were dissociated using collagenase D (Roche), and
single cells were stained with either Alexa Fluor 647-conju-
gated cleaved caspase-3 Ab or FITC-conjugated annexin V Ab
(BD Biosciences). Flow cytometric analysis was performed
using a BD FACScan unit using CellQuest software (BD
Immunocytometry Systems; BD Biosciences).
Western blot
Parental cells or established stable clones (1833, 1833-CR,
D54, and D54-CR cells) were washed in PBS and lysed with
RIPA buffer (Invitrogen, Carlsbad, CA, USA) including com-
plete protease inhibitor cocktail (Roche). The protein con-
centration was estimated using a bicinchoninic acid (BCA) kit
(Pierce, Rockford, IL, USA). The media and lysates were
separated by SDS-PAGE, and protein expression was detected
by Western blot analysis using antibodies (Abs). Equal
amounts of protein were loaded in each lane and resolved by
4–12% gradient Bis-Tris gel (Invitrogen). Proteins were trans-
ferred to 0.2 m polyvinylidene difluoride (PVDF) mem-
brane (Invitrogen). Membranes were blocked and incubated
overnight at 4°C with primary Abs and then incubated with
the appropriate horseradish peroxidase (HRP)-conjugated
secondary antibody at room temperature for 1 h. ECL-Plus
(Amersham Pharmacia, Uppsala, Sweden) was used to detect
peroxidase activity according to the manufacturer’s protocol.
Abs raised against luciferase, caspase-3, poly(ADP-ribose)
polymerase (PARP), and -actin were purchased from Cell
Signaling Technology (Beverly, MA, USA).
In vivo NK therapy
D54-CR cells (5106) were subcutaneously implanted into
the right hind flanks of nude mice (n30). When tumor
formation was detected, the mice were divided into 3 groups:
a control group for PBS treatment and 2 therapy groups for
NK92 cell (2106 and 1107 cells/mouse, respectively) treat-
ment. After injection, BLI was acquired to monitor caspase-3
activation as well as Rluc gene for therapeutic response at the
indicated times.
BLI of the caspase-3 sensor and Rluc gene was obtained
using an IVIS Lumina II (Perkin-Elmer, Wellesley, MA, USA)
immediately before injection and 12, 24, and 48 h after
administration of NK92 cells. Mice received a single dose of
substrate for each reporter (d-luciferin or coelentrazine, 3
mg/mouse or 15 g/mouse, respectively; Perkin-Elmer)
when BLI was performed at each time point. Mice were
anesthetized with a 1–2% isofluorane/air mixture, and serial
images were acquired over 20–30 min to capture the peak
photon emission for each animal. Regions of interest were
drawn around the area of interest in each mouse, and peak
luminescence values of each series were used for analysis. The
fold increase of induction for the caspase-3 sensor was calcu-
lated by dividing the BLI activity of the caspase-3 sensor
(cellular apoptosis) by the BLI activity of Rluc gene (cell
viability) at each time point.
Statistical analysis
All data are expressed as means  sd, and statistical signifi-
cance was determined using an unpaired Student’s test. The
statistical significance and the error bars for FACS analysis
were determined using ANOVA, which determines the mean
differences between each group. Values of P 	 0.05 were
considered statistically significant.
RESULTS
Establishment of reporter tumor cells for both
caspase-3 activation and cellular viability
For monitoring caspase-3 activation and the therapeu-
tic response of target cancer cells to NK therapy, we
successfully established stable cell lines expressing 2
reporters; a caspase-3 sensor construct as a caspase-3
proteolysis marker and the renilla luciferase gene as a
surrogate marker of cell viability. Western blot analysis
using anti-luciferase Ab showed luciferase protein for
caspase-3 sensor (
69.3 kDa) in D54-CR and 1833-CR
cells but not parental cells (Supplemental Fig. S1A).
The BLI signal of the Rluc gene was increased in a cell
number-dependent manner in D54-CR and 1833-CR
cells but not in either line of parent cells (R20.86 and
R20.92, D54-CR and 1833-CR, respectively; Supple-
mental Fig. S1B, C).
Treatment of D54-CR and 1833-CR cells with rTRAIL
resulted in a time- and dose-dependent increase in BLI
activity compared with cells subjected to PBS treatment
(Supplemental Fig. S1D, E).
As shown in Supplemental Fig. S1F, the percentages of
cleaved caspase-3-positive cells increased according to
TRAIL dose (1-way ANOVA, P	0.0001), revealing a good
correlation between caspase-3 activation and the level of
cleaved caspase-3 (R20.95; Supplemental Fig. S1G).
Monitoring of caspase-3 activation by NK92 cell
cytotoxicity in vitro
To demonstrate caspase-3 activation by the therapeutic
effects of NK92 cells in vitro, NK92 cells were incubated
with D54-CR and 1833-CR cells at T:E ratios of 1:2.5,
1:5, and 1:10, and BLI signals were measured. Incuba-
tion of D54-CR cells with NK92 cells led to a time- and
dose-dependent increase in BLI activity compared with
cells treated with PBS (Fig. 1A, B); peak activity in the
BLI signal of the caspase-3 sensor at all T:E ratio was
measured 4 h post-treatment. Consistent with the in-
crease in BLI activity of the caspase-3 sensor, Western
blot analysis of D54-CR cells also revealed increases in
cleaved PARP protein in a dose-dependent manner
(Fig. 1C) and subsequently showed a time-dependent
increase in caspase-3 activation as measured by cleavage
of capsase-3 and PARP (Fig. 1D).
Interestingly, the caspase-3 sensor showed the differ-
ent susceptibility of breast and glioma cancer cells to
NK92 cells in vitro. As illustrated in Fig. 1E, the suscep-
tibility of D54-CR cells to NK92 cells was higher than
that of 1833-CR cells, resulting in a peak in BLI activity
at 4 h post-treatment (D54-CR cells and 1833-CR cells,

24.6 and 
6.6-fold induction, respectively).
Inhibition studies were performed to examine the
selectivity of the caspase-3 sensor using Z-VAD-FMK, wort-
mannin, and PD98059, and the following results were
obtained. First, treatment with NK92 resulted in an
18.5-
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fold induction in BLI activity 5 h after NK92 treatment to
D54-CR cells compared with vehicle treatment, while BLI
activity (showing the caspase-3 activation) in cancer cells
treated with NK92 was almost completely blocked by
Z-VAD-FMK (Fig. 2A). Caspase-3 activation was not de-
tected in D54-CR cells incubated with either vehicle or
Z-VAD-FMK alone. Second, treatment of wortmannin led
to decreases in BLI activity in D54-CR cells incubated with
NK92 cells, while NK92 treatment resulted in a
19.4-fold
increase in BLI activity compared with cells treated with
vehicle only (Fig. 2B). Treatment with PD98059 also
resulted in a drastic decrease in BLI activity in D54-CR
cells treated with NK92 cells; an 
19.2-fold increase in
BLI activity in D54-CR cells was observed following NK92
treatment (Fig. 2C).
We evaluated whether the caspase-3 sensor could show
modulated cytotoxicity when NK92 cells were stimulated
with specific agents such PMA and ionomycin, leading to
promotion of cytokine secretion [tumor necrosis factor
(TNF) and interferon  (IFN-)]. Stimulation of NK92
cells resulted in amore rapid and higher fold induction in
BLI activity of the caspase-3 sensor in D54-CR cells com-
pared with nonstimulated NK92 cells (Fig. 2D).
In vivo imaging of capsase-3 activation following
adoptive transfer of NK92 cells to D54-CR tumor
model and evaluation of its antitumor effects
Adoptive transfer of either PBS or NK92 cells in D54
tumor-bearing mice resulted in an increase in BLI
Figure 1. Change in caspase-3 sensor activity by in vitro
treatment of NK92 cells. A, B) Increase in caspase-3 sensor
activity following NK92 treatment. Stable D54-CR (A) and
1833-CR (B) clones were plated in 96-well plates, and NK92
cells were added to each well at a different T:E ratio; BLI
activity (caspase-3 sensor and Rluc gene) was then measured
at every hour for 6 h. C, D) Representative Western blots of
lysates from NK92-treated D54-CR cells using anti-cleaved
PARP (C, D) and caspase-3 (D) Abs. D54-CR cells were
treated with NK92 cells, and cell lysates were prepared for
Western blot analysis. Lysates were probed with -actin Ab to
control for loading. E) Varying susceptibility of stable clones
(D54-CR and 1833-CR) against NK92 killing. Stable clones
of D54-CR and 1833-CR cells were plated in 96-well plates,
and effector was added to target cells 24 h later at a T:E ratio
of 1:5. BLI activity for the caspase-3 sensor or Rluc gene was
measured and plotted as fold induction over values obtained
from vehicle-treated cells. BLI activity of the caspase-3 sensor
was normalized with that of theRluc gene. Experiments were
performed at least in triplicate; values are means  sd.
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activity of the caspase-3 sensor depending on the num-
ber of administered effectors when images were ac-
quired at the indicated times (Fig. 3A, B). Differences
in BLI activity of the Rluc gene were not detected
between the PBS treatment group and the NK92 treat-
ment group 24 h post-treatment (data not shown).
FACS analysis of the excised tumors with anti-cleaved
caspase-3 Ab revealed an increase in cleaved caspase-3
levels in tumors treated with NK92 cells compared with
those treated with PBS, showing an increase in active
caspase-3-positive cells by increasing the number of
effector cells (Fig. 3C).
Antitumor effects induced by NK-based immunother-
apy were also monitored in D54-CR tumor-bearing
mice by evaluating the level of caspase-3 activation
using the caspase-3 sensor, as depicted in Supplemental
Fig. S2. The BLI activity of the caspase-3 sensor from
tumors was not increased in mice treated with PBS.
However, adoptive transfer of NK92 cells to D54-CR
tumor-bearing mice resulted in an increase in the BLI
activity of the caspase-3 sensor immediately after treat-
ment (Fig. 4A, B). Particularly, repeated treatment with
NK92 cells resulted in an increase in the cumulative
BLI activity of the caspase-3 sensor until d 15, after
which time BLI activity declined. Treatment with a
higher number of NK92 cells (1107 cells) resulted in
greater increases in BLI activity of the caspase-3 sensor
from tumors compared with mice treated with lower
numbers of NK92 cells (2106 cells). Mice receiving
either 2  106 or 1  107 NK92 cells had an 
12.5 and

18.2 maximum fold increase in BLI activity of the
caspase-3 sensor, whereas PBS-treated mice had a min-
imal increase in BLI activity of the caspase-3 sensor.
When the peak activity of the caspase-3 sensor was
detected at d 15, tumors were excised, and single cells
were isolated to further determine levels of both
cleaved capsase-3 and annexin-V in tumors from mice
receiving either PBS or varying numbers of NK92 cells.
FACS analysis demonstrated that tumors from NK92-
treated mice showed an increase in active capsase-3
levels in an NK92 cell number-dependent manner
compared with those from PBS-treated mice (Fig. 4C).
Consistent with the cleaved caspase-3 results, apoptosis
analysis with anti-annexin V Ab demonstrated that the
increase in annexin-V levels in tumors from mice
Figure 2. Measurement of selectivity of NK92-mediated killing against target cells with caspase-3 sensor. A–C) Inhibition of
caspase-3 sensor activity by treatment with Z-VAD (A), wortmanin (B), and PD 98059 (C), which block the signaling pathways
leading to apoptosis and cytotoxicity. D54-CR cells were plated in 96-well plates, and the indicated compounds were added to
target cells for 1 h. Then, NK92 cells were added to the target cells at a T:E ratio of 1:5. BLI activity of the caspase-3 sensor or
Rluc gene was measured. D) Enhanced cytotoxicity of NK92 cells by combined treatment of PMA and ionomycin. NK92 cells
were treated with or without a combination of PMA and ionomycin for 2 h. Nonstimulated and stimulated NK92 cells were
coincubated with D54-CR cells at T:E ratio of 1:2.5, and BLI activity (caspase-3 sensor and Rluc gene) was measured every hour
for 5 h. BLI activity was plotted as fold induction over the values obtained from vehicle treated cells. BLI activity of the caspase-3
sensor was normalized with that of Rluc gene. Experiments were performed at least in triplicate; values are means  sd.
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receiving NK92 cells was proportional to the number of
infused NK92 cells (Fig. 4D).
In vivo imaging of tumors using a Rluc reporter gene
revealed that treatment with lower numbers of NK92
cells resulted in moderate retardation of tumor growth
compared with the PBS-treated group. Particularly,
mice treated with high doses of NK92 cells exhibited
marked retardation of tumor growth compared with
mice treated with low doses of NK92 cells. At d 18 after
treatment, PBS-treated mice exhibited a 170% increase
in BLI activity, whereas mice treated with a lower or
higher dose of NK92 cells showed an increase of 49 and
4.9% in BLI activity, respectively (Fig. 5). When tumor
volume was measured with calipers, a delay in tumor
growth was observed in the NK92 treated group but not
in the PBS-treated group from d 4 until d 18 after in
vivo therapy, which is consistent with the results of in
vivo BLI of the Rluc gene (Supplemental Fig. S3).
However, inhibition of tumor growth was not observed
in the PBS treated group during in vivo therapy.
DISCUSSION
Intense attention has been given to NK cell-based
immunotherapy as a potentially effective therapeutic
tool, because of its selective killing effect against cancer
cells (11). Recently, a number of clinical approaches
have been used to evaluate the possibility of NK therapy
in a variety of cancers. However, it has been difficult to
achieve promising outcomes in clinical cases because of
the unsuitable ratio of effector to target cells, weak
cytotoxicity, tumor targeting of an insufficient number
of effectors, and hindrance of immuomodulatory cyto-
kines or immune cells. Effective strategies for improv-
ing NK cell-based immunotherapy remain to be further
investigated.
Serial molecular events related to apoptosis in cul-
tured cells and/or animal tumor models induced by
newly developed NK cell therapy have been evaluated
with traditional immunological and biochemical tech-
niques such as the 51Cr release assay, lactate dehydro-
Figure 3. In vivo imaging of caspase-3 activation by NK92
cells treatment. A) In vivo imaging of caspase-3 activation
following adoptive transfer of NK92 cells to D54-tumor
bearing mice. When a tumor was detected by palpation and
inspection, NK92 cells (2106 or 1107 cells/mouse) were transfused to tumor-bearing mice, and BLI was acquired at the
indicated time. B) Quantification of caspase-3 activation. C) FACS analysis to evaluate both cleaved caspase-3 and annexin
V levels. At the end of the animal study, tumors were excised and further processed for FACS analysis. Either the cleaved
caspase-3 or apoptosis level was determined in isolated cells from the tumor tissue of mice receiving either PBS or NK92 at
different T:E ratios with anticleaved caspase-3 Ab. Mcherry fluorescent protein is the surrogate marker for Rluc gene. Bars
represent percentage of cleaved caspase-3-positive cells. BLI activity was plotted as fold induction over values obtained from
vehicle-treated cells. BLI activity of the caspase-3 sensor was normalized with that of the Rluc gene. Experiments were
performed at least in triplicate; values are means  sd.
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genase (LDH) assay, flow cytometry, and protein-based
assays such as Western blotting. These analytical tools
only allow a nonquantitative snapshot of the interactive
cascade of signaling events following therapeutic inter-
vention and can overlook the time-and dose-dependent
molecular effects during evaluation of NK cytotoxicity.
Thus, innovative imaging tools are needed to enable
real-time monitoring of the sequential cellular events of
apoptosis induced by cell therapies such as NK-based
immunotherapy.
The present study utilized a genetically engineered
caspase-3 sensor for the dynamic and quantitative im-
aging of apoptotic molecular events in living animals.
We previously reported a caspase-3 biosensor based on
a split luciferase system (10). This apoptosis sensor is
made of the split luciferase domains fused to interact-
ing peptides, pepA and pepB, with an intervening
caspase-3 cleavage motif [aspartic acid-glutamine-va-
line-aspartic acid (DEVD) sequence]. On induction of
apoptosis, this sensor is proteolytically cleaved by
caspase-3 at the DEVD motif, and this cleavage induces
the reconstitution of luciferase activity through the
interaction of NLuc and CLuc. Here, we attempted to
not only monitor the activation of apoptosis induced by
NK therapy in a glioma cancer model in vitro and in vivo
using a caspase-3 sensor but also evaluate the therapeu-
tic effects of NK therapy using a Rluc reporter gene
system.
Figure 4. Application of caspase-3 sensor in experimental setting of NK-based immunotherapy. A) Representative BLI
(showing the maximum caspase-3 activation) from D54-CR tumor-bearing mice before and after treatment with NK92 cells.
When a tumor was detected by palpation and inspection, NK92 cells (2106 or 1107 cells/mouse) were intravenously
transferred to tumor-bearing mice at the indicated time, and BLI was acquired. B) Quantification of caspase-3 activation.
BLI activity was plotted as fold induction over values obtained from vehicle-treated cells. BLI activity of the caspase-3 sensor
was normalized with that of Rluc gene. C, D) FACS analysis to evaluate either the cleaved caspase-3 (C) or annexin-V (D)
level. At the end of the animal study, tumors were excised and further processed for FACS analysis. Either cleaved caspase-3
or apoptosis levels were determined in isolated cells from the excised tumor tissue of mice receiving either PBS or NK92
cells at different T:E ratios with anti-cleaved caspase-3 or annexin V Abs. Mcherry fluorescent protein is the surrogate
marker for Rluc gene. Bars represent percentage cleaved caspase-3- or annexin-V-positive cells. Experiments were
performed at least in triplicate; values are means  sd.
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NK92 cells (IL-2-dependent and highly activated NK
cells) were adopted as an effector in the current study
because NK92 cells are reported to have high killing
effects against various cancer cells, including myeloma,
leukemia, malignant lymphoma, melanoma, ovarian,
bladder, and breast cancer, in preclinical or clinical
settings (12, 13), and they are easy to handle with
simple supplementation of IL-2. Breast and glioma
cancer cells expressing a caspase-3 sensor construct
were established as target cells. An Rluc reporter gene
was further transduced in target cells using a lentiviral
system because it enables quantification of cellular
viability, which is an important factor in apoptosis-
related studies. Thus, stable cells expressing both a
caspase-3 sensor and an Rluc gene may be able to
simultaneously detect caspase-3 activation as well as
determine cellular viability after NK92 treatment.
Several studies have demonstrated that TRAIL in-
duces extrinsic apoptosis by binding death receptor
(DR4/5) and activates effector caspase-3 (14–16). Us-
ing rTRAIL, we also confirmed that the functional
activity of the caspase-3 sensor after rTRAIL treatment
of stable clones of D54-CR and 1833-CR is increased, as
shown by increased BLI activity in caspase-3 sensor in a
dose- and time-dependent manner. FACS analysis with
anti-cleaved caspase-3 Ab also demonstrated the in-
crease in cleaved caspase-3 levels in rTRAIL-treated
D54-CR cells in a dose-dependent manner; a good
correlation was observed between caspase-3 activation
and the level of cleaved caspase-3. Furthermore, the
BLI activity of Rluc showed a decrease in cell viability in
the same manner. These findings suggest that the BLI
activity of the caspase-3 sensor is representative of the
level of caspase-3 activation that occurs in cancer cells
even before cell death by treatment with immune
effector cells.
In accordance with our rTRAIL experiment data,
treatment of NK92 cells resulted in an increase in the
BLI activity of the caspase-3 sensor in a time- and
dose-dependent manner in vitro. These findings are
consistent with the results of the Western blot analysis
for caspase-3 activity, as determined by both cleavage
caspase-3 and PARP Ab. Furthermore, we determined
the selectivity of the caspase-3 sensor in NK-mediated
apoptosis with specific apoptosis inhibitors. Treatment
of NK92 cells resulted in strong BLI activity in D54-CR
cells, but caspase-3 activation was effectively inhibited
with three different inhibitors (Z-VAD, wortmannin,
and PD98059). These compounds are well known to
inhibit sequential signaling events, such as caspase,
PI3K, and extracellular signal-regulated kinase (Erk),
which are associated with the activation of apoptosis
induced by NK cell-mediated cytotoxictiy. These find-
ings suggest that specific cellular signaling events re-
lated to caspase-3 activation generated by NK cell
cytotoxicity can be monitored in live cells, which is
essential for the optimization of NK cell-based therapy.
Improving NK-mediated cytotoxicity by modulating
effector cells with cytokine genes and chemical com-
pounds such as PMA and ionomycin is an essential
element to achieving more successful therapeutic ef-
fects before adoptive transfer of NK cells in vivo (17–
20). It was reported that the combination of the protein
kinase activator PMA and the ionomycin increased
robust secretion of the cytokines TNF and IFN- and
resulted in accelerated cellular apoptosis (21, 22). In
our in vitro study of applying PMA/ionomycin to NK92
cells, we also observed a more rapid increase and
higher levels of the BLI signals of the caspase-3 sensor
following stimulation of NK92 cells with 2 compounds.
Moreover, we observed different susceptibilities to
NK92 cell therapy between breast cancer cells (1833-
CR) and glioma cancer cells (D54-CR) using the
caspase-3 sensor. These findings should be an impor-
tant issue when designing the tailored strategies of
NK-based therapy. For example, when breast cancer
cells are not susceptible to NK cells during early
screening of NK cell cytotoxicity against cancer cells, a
combination of NK therapy and other therapeutic
strategies such as radiation and chemotherapy, which
has reported to modulate the phenotype marker of
cancer cells as well as increase the susceptibility of
target cells (23–27), could be considered. If combina-
tions of different methods with NK cells could be
properly selected for breast cancer cells, increases in
the BLI signals of the caspase-3 sensor would be greater
after combination treatment.
Figure 5. In vivo monitoring of antitumor effects of NK
therapy by optical imaging using the Rluc reporter gene. A)
Monitoring the antitumor effects by NK-based immunother-
apy. BLI activity was measured at the indicated times to
monitor tumor progression. B) Quantification of BLI activity
in the Rluc reporter gene. BLI was obtained on initiation of
NK92 cell therapy at the indicated times, and regions of
interest analysis of BLI activity in the tumors was performed to
evaluate the therapeutic response of NK92 therapy. Bars
represent relative change in BLI activity of the treatment
group compared with the control group. Experiments were
performed at least in triplicate, values are means  sd.
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D54-CR cells were used for the target animal tumor
model in our in vivo study because D54 target cells were
shown to be more susceptible to NK92 therapy than
1833 breast cancer cells as depicted in Fig. 1E. In vivo
caspase-3 activation was noninvasively monitored fol-
lowing an adoptive transfer of different doses of NK92
cells to D54-CR tumor bearing mice. Increase in the
BLI signal of the caspase-3 sensor was observed in an
effector number- and time-dependent manner, which is
consistent with an increase in cleaved caspase-3 levels in
isolated cells from tumor tissues. Normally, we can
observe the peak BLI activity (showing the caspase-3
activation) in tumors of treated mice at 3 h after
injection. Although the migration of infused NK cells
was not monitored using an in vivo imaging modality,
we can presume that infused NK92 cells may localize to
the tumor site at early time points (within 3 h) and
attack and kill target cells, resulting in an increase in
caspase-3 BLI activity and a decrease in Rluc activity.
These findings are also consistent with the report of
Melder et al. (28), in which animal PET imaging with
11C methyl iodide was used for successful monitoring of
the migration of NK cells in tumor-bearing mice.
Localization of labeled NK cells in tumor vasculature
was observed at 30 min to 1 h postinjection in their
study.
For an in vivo setting of NK cell therapy, as shown in
Fig. 5A, repeated transfusion of either higher or lower
numbers of NK92 cells resulted in a gradual increase in
BLI activity of the caspase-3 sensor during the course of
treatment, revealing that treatment with a higher dose
of NK92 cells is more effective in the induction of
caspase-3 dependent apoptosis than a lower dose. Fur-
thermore, when tumor growth by NK92 therapy was
serially monitored using the Rluc reporter gene, higher
dose treatment was more effective for inhibition of
tumor growth compared with lower dose treatment.
Based on the current results, we believe that the
caspase-3 sensor could be extended to the DNA or
dendritic cell (DC) vaccine-based immunotherapy
field; DNA or DC vaccination leads to the tumor-
specific immune response through antigen presenta-
tion of antigen-presenting cells (APCs) and subsequent
stimulation of effectors [such as cytotoxic T cells
(CTLs)] against cancer. Particularly, antitumor immu-
nity is mainly dependent on successful activation and
expansion of effector T cells, and thus, an imaging
modality to noninvasively show the killing effects of
effector T cells would be of considerable benefit for
therapeutic setting optimization of DNA or DC-based
immunotherapy.
There are some issues to address concerning the
limitations of the current study. First, immunodeficient
nude mice and the NK92 cell line were used to evaluate
the therapeutic effects of NK-based immunotherapy;
we adopted human cancer cells for the target because
there are many different factors to be considered in the
tumor microenvironment between immunodeficient
and immunocompetent mouse systems. Thus, testing
the potentials of caspase-3-sensor in immunocompetent
mice with primary NK cells was required. Second, the
caspase-3 sensor is based on a plasmid vector system,
and the steps of transferring the sensor vector to target
cells and selecting stable clones are undertaken during
procedure. The original phenotype and character of
cancer cells could be modified during the establish-
ment of stable cell lines, which may affect the cytotox-
icty of NK cells as an essential function of effectors.
Thus, changes in the original character of cancer cell
should be compared between parental cells and stable
cells in a future study.
In summary, we successfully visualized cellular
apoptotic events induced by NK cell therapy nonin-
vasively both in vitro and in vivo using a caspase-3
biosensor. The BLI findings were well correlated with
the antitumor effects of therapy in vivo. A molecular
imaging technique with a caspase-3 sensor would
facilitate preclinical evaluation of therapeutic proto-
cols, including dosing, scheduling, and efficacy of
NK-based immunotherapy.
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